Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 April 2023 | Story Leonie Bolleurs | Photo Leonie Bolleurs
reusable sanitary pads
A team of researchers from the UFS is part of a project to invent a reusable sanitary pad that is safe, hygienic, comfortable, easy to use, and friendly to the environment. From left are: Prof Katinka de Wet, Dr Marietjie Schutte-Smith, Prof Deon Visser, and Prof Lizette Erasmus.

A new reusable sanitary pad (RSP) will bring relief to many women during their menstrual cycle.

Dr Marietjie Schutte-Smith, Senior Lecturer in the University of the Free State (UFS) Department of Chemistry, together with Prof Deon Visser, Head of the Department of Chemistry, and Prof Lizette Erasmus, Associate Professor in the same department, are leading a diverse team that decided 18 months ago to do something about the challenge of not having access to conventional sanitary ware and water due to poverty and infrastructure challenges – a challenge many young women in South Africa face every month.

The team included Prof Katinka de Wet, Associate Professor in the Department of Sociology, in this process in an effort to gain a better understanding of the current perceptions, experiences, and preferences of those who will ultimately use these sanitary products. 

“We wanted to do research that has a direct and tangible impact on our immediate society,” says Prof Erasmus. 

New technology

The research team turned their focus to reusable sanitary pads (RSPs), specifically the invention of a product that can be cleaned without being exposed to direct sunlight. 

Dr Schutte-Smith explains that most RSPs must be exposed to direct sunlight to dry and prevent bacterial growth. “Exposing RSPs to sunlight is challenging for users residing in densely populated areas, besides the fact that many people find the public display of sanitary products embarrassing.”

She believes a product that can be washed and left indoors to dry, one that has antibacterial and antimicrobial properties under normal light conditions, and with durable superabsorbent inner layers, could alleviate some of these challenges.

The team then started working on technology including nanoparticles (NPs) that affix to textiles and will kill germs and fungi when exposed to normal light. 

Prof Erasmus says, “Attaching NPs to materials is not a new concept, however, the use of nanoparticles that are activated by normal light conditions is new… Also, we have synthesised several absorbent materials using natural fibres and biopolymers as the main constituents. This is an ongoing process to enhance their absorbent properties and durability so that they can be included in our product.”
We wanted to do research that has a direct and tangible impact on our immediate society. – Prof Lizette Erasmus

She adds that when the RSPs are eventually discarded (after four to five years) they will break down in the environment and not contribute further to the plastic waste problem the world is facing. Most disposable sanitary pads (DSPs) are not environmentally friendly and take 500 to 800 years to decompose. 

Dr Schutte-Smith goes on to explain that the sanitary ware will be manufactured by sewing different layers together. “The outer lower layer will consist of a hydrophobic (fluid-repellent) layer to prevent leaking, and the inner layer will consist of the synthesised and biodegradable superabsorbent polymer (SAP).”

The product will be mixed into cotton and will be removable (for better cleaning). “It will also contain NPs that use natural indoor light to disinfect. The top layer also contains our nanotechnology and will relay fluids to the absorbent inner layer.”

Social implications

Besides the important work being done by chemists to incorporate technology that will ensure the product makes sense scientifically, it is also important that the experiences, perceptions, and ideas of end users are kept in mind. 

Prof De Wet says social scientists were included in the design and development of this product to ensure that the actual needs of the end users are taken into consideration. The idea is to collaborate with school learners and university students to get their feedback on the development and eventual use of these newly developed RSPs.

“The aim, therefore, is to sensitise menstruating individuals as to the possible personal advantages of using reusable sanitary pads, including that it is less expensive in the long run, thus eliminating the problem of access to quality and reliable sanitary ware. There could even be some potential health advantages to using such products, as current disposable products contain phthalates that have been shown to have adverse health effects on individuals,” she states.

Prof De Wet also points out the environmental benefits of using reusable sanitary products, and the importance of sensitising young people to the environmental costs of single-use plastic consumption, of which sanitary ware is a major contributor. “Environmental consciousness is part of the social side of the project, given the pressures globally on the human-induced impact on our planet, and its devastating consequences,” she says. “We want the science (chemistry) to have a real social impact in people’s lives individually, socially, and environmentally.”

Future steps

According to Prof Visser, the team already has a prototype in place, which now needs to be perfected through inputs from end users. They hope to have an industry partner within the next six months that will help to get this product on the market.  

The team of chemists worked hard to develop a product that will have the potential to change many lives for the better, allowing young girls and women to thrive in life. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept